Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Optimizing complement-activating antibody-based cancer immunotherapy: a feasible strategy?

Ester Fonsatti1, Anna Maria Di Giacomo, Michele Maio

  • 1Cancer Bioimmunotherapy Unit, Department of Medical Oncology, Centro di Riferimento Oncologico, I,R,C,C,S, 33081 Aviano, Italy. mmaio@cro.it

Journal of Translational Medicine
|June 29, 2004
PubMed
Summary

Monoclonal antibodies (mAbs) offer promising cancer immunotherapy, but efficacy is limited. Targeting membrane complement-regulatory proteins like Protectin (CD59) could enhance mAb effectiveness in cancer treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing the Impact on Health and Productivity Outcomes of Anti-PD-(L)1 Agents to Treat Early-Stage Cancers in Italy.

Clinical drug investigation·2026
Same author

Circulating EV-microRNAs are dynamic biomarkers of resistance to therapeutic immunomodulation in metastatic melanoma.

Communications medicine·2026
Same author

Discontinuation of combo immunotherapy and outcome of patients with melanoma brain metastases.

Journal for immunotherapy of cancer·2026
Same author

Tumor DNA methylation subtypes predict immunotherapy outcomes in pleural mesothelioma patients in the NIBIT-EPI-MESO study.

Nature genetics·2026
Same author

Fulzerasib plus cetuximab in first-line KRAS<sup>G12C</sup>-mutated non-small-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial.

The Lancet. Oncology·2026
Same author

A Real-World Experience of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma.

Cancers·2026

Area of Science:

  • Oncology
  • Immunology
  • Biochemistry

Background:

  • Monoclonal antibodies (mAbs) are a rapidly growing area of cancer biological therapy.
  • Limited clinical efficacy of therapeutic mAbs has been observed in selected neoplasias.
  • Optimizing mAb therapy requires deeper characterization of neoplastic cell biological features.

Discussion:

  • Focusing on membrane complement-regulatory proteins, such as Protectin (CD59), is crucial.
  • Protectin (CD59) normally protects tissues from complement-mediated damage.
  • Understanding its role can refine antibody-based immunotherapy strategies.

Key Insights:

  • Identifying specific biological features of cancer cells is key to improving mAb therapy.
  • Therapeutic potential of mAbs can be optimized by understanding these features.

Related Experiment Videos

  • Identifying ideal candidates for antibody-based immunotherapy is essential.

    • Outlook:

    • Investigating the tissue distribution and function of Protectin (CD59) can enhance efficacy.
    • Complement (C)-activating mAb strategies may be optimized by targeting these proteins.
    • This approach could lead to more effective cancer treatment options.